Ladies & Gentlemen of the Jury...I Mean Advisory Committee
This article was originally published in RPM Report
Executive Summary
When King Pharmaceuticals Inc. Chief Scientific Officer Eric Carter concluded his presentation during the April 22 advisory committee review of the novel oxycodone/niacin formulation Remoxy, he sounded almost like an attorney making a closing argument before a jury.